Medications
Retatrutide Side Effects: What the Phase 3 Trials Actually Reported
Most of what has been written about retatrutide side effects is working from the 2023 Phase 2 study, which enrolled 338 people. There is now Phase 3 data from more than 3,300 participants across three trials, and the newest of them reported in May 2026. The side effect picture that emerges from the larger dataset is different in one important respect, and it is the part that keeps getting left out.
What retatrutide is
Retatrutide is a single molecule that activates three receptors: GIP, GLP-1, and glucagon. Semaglutide activates one of those. Tirzepatide activates two. Adding the glucagon receptor is what separates retatrutide from both, and it is also the most likely explanation for several of the side effects below.
The name that circulates online for this class, GLP-3, does not describe anything. There is no third GLP receptor. The correct description is a triple agonist, and the distinction matters because the glucagon arm is doing real work in both the results and the adverse events.
Where the numbers come from
Four studies carry the data. Any article citing retatrutide side effects without naming which trial a number came from is worth skipping.
| Study | Reported | Participants | Duration | Top dose weight loss |
|---|---|---|---|---|
| Phase 2 (Jastreboff, NEJM) | June 2023 | 338 | 48 weeks | 24.2% at 12 mg |
| TRIUMPH-4 | December 2025 | 445 | 68 weeks | 28.7%, about 71.2 lb, at 12 mg |
| TRANSCEND-T2D-1 | March 2026 | 537 | 40 weeks | 16.8% at 12 mg |
| TRIUMPH-1 | May 2026 | 2,339 | 80 weeks | 28.3%, about 70.3 lb, at 12 mg |
TRIUMPH-1 is by a wide margin the largest and longest of these, and in a subgroup of participants with a BMI of 35 or above who continued to 104 weeks, weight loss reached 30.3 percent. Almost none of the pages currently ranking for this search reference it, because most of them were written before it reported.
The pattern across all four is consistent. Weight loss climbs with dose, and so does everything else.
The side effects, by dose
The gastrointestinal effects are the ones every article covers, and they are genuinely dose dependent rather than uniform. Across the trials, nausea runs from roughly 11 to 14 percent at low doses and placebo up to 43 to 60 percent at 9 and 12 mg. Vomiting runs from about 1 to 4 percent at low doses up to 21 to 26 percent at 12 mg. Diarrhea and constipation follow the same shape.
The number I pay the most attention to is discontinuation, because it measures what people could actually live with rather than what they reported at a visit.
In TRIUMPH-4, 18.2 percent of participants on 12 mg stopped because of adverse events, against 12.2 percent at 9 mg and 4.0 percent on placebo. In the much larger TRIUMPH-1, discontinuation at 12 mg was 11.3 percent. The honest reading is that somewhere between one in nine and one in five people at the top dose could not stay on it, and the larger trial sits at the better end of that range.
Retatrutide is not available outside a trial yet
Every vial being sold as retatrutide today comes from a grey market source, with no manufacturing oversight and no way to confirm the contents or the dose. Tirzepatide and semaglutide are approved and available now.
Dysesthesia, and why it changes the calculation
Dysesthesia is an abnormal skin sensation. Patients describe burning, tingling, tightness, tenderness to light touch, or heightened sensitivity to temperature and pressure, in the absence of anything touching the skin. It is a neurological symptom rather than a dermatologic one, which is why it belongs in a different category from nausea.
The reported rates differ substantially between trials, and any article giving you a single number is picking one.
TRIUMPH-4 reported dysesthesia in 20.9 percent of participants on 12 mg and 8.8 percent on 9 mg, against 0.7 percent on placebo. TRIUMPH-1, which enrolled more than five times as many people, reported 12.5 percent at 12 mg against 0.9 percent on placebo. TRANSCEND-T2D-1 ran lower still, at 2.3 to 4.5 percent across doses. In the earlier Phase 2 study, a related finding, cutaneous hyperesthesia, appeared in about 7 percent against 1 percent on placebo.
So the range at the top dose runs from roughly one in twenty in the diabetes trial to one in eight in the largest obesity trial to one in five in the knee osteoarthritis trial. Different populations, different durations, and a symptom that depends heavily on how you ask about it. What is consistent across every trial is that the rate is many times the placebo rate and it climbs with dose.
It became widely discussed only after TRIUMPH-4 reported in December 2025, which is why articles written before that date do not mention it, and several written after it quote the 20.9 percent figure without the TRIUMPH-1 number that followed.
The proposed mechanism involves the glucagon receptor, which would make it a class effect specific to triple agonists rather than something that carries over from semaglutide or tirzepatide. That remains a hypothesis. What is not in dispute is the incidence.
Here is why it matters more outside a trial than inside one. Every participant in TRIUMPH-4 was being monitored, had a defined dose escalation schedule, and had a physician who could pause or stop the drug when a symptom appeared. Someone escalating a research compound on their own has none of that, and a new burning or tingling sensation in the hands or feet is exactly the kind of symptom that gets attributed to something else and pushed through.
The regulatory reality
Retatrutide is not approved by the FDA or by any regulator anywhere in the world. It is available legally only inside Eli Lilly’s clinical trials, and Lilly’s published position on everything else is that “anything sold to consumers outside of those trials is illegal, with no way to verify its safety, purity or dosing.”
That rules out every other source. There is no pharmacy that can lawfully fill a prescription for it, because there is no approved product to fill. Anything sold as retatrutide outside a trial was manufactured by someone with no FDA oversight, no assay you can inspect, and no obligation to tell you what is actually in the vial. The FDA issued a warning letter in September 2025 to a seller distributing semaglutide, tirzepatide, and retatrutide products outside the approved pathway.
Estimates for approval, if the Phase 3 program is successful, generally land no earlier than 2027.
Most GLP-1 side effects are a dosing problem
Nausea that never settles usually follows a titration that moved too fast. Slowing the escalation is a prescribing decision, and it is worth asking for before you decide the drug does not work for you.
What I watch for
I am not opposed to this drug. The TRIUMPH-1 result, 28.3 percent average weight loss sustained to 80 weeks in a trial of 2,339 people, is the closest a medication has come to surgical outcomes. If it is approved as reported, it will change what I recommend to a subset of my patients.
The concern is the gap between that data and what people are doing with it right now. The trial participants got a supervised titration, regular monitoring, and a stop rule. The person buying a vial off a website gets a number on a label. When between 11 and 18 percent of people at the top dose could not stay on it under supervision, self titration to that dose is not a small risk.
If you are using something you bought as retatrutide, come in and let me look at it. The things I would want checked are liver enzymes, resting heart rate, and any new sensation in the hands or feet. And I would want to know the actual dose, which for most people buying reconstituted vials is a guess.
Common questions
Is retatrutide stronger than tirzepatide? In the trials to date, retatrutide has produced larger average weight loss than what has been reported for tirzepatide, but the two have never been compared head to head in a randomized trial. Cross-trial comparisons between different populations, durations, and protocols are not reliable evidence of superiority.
What is the retatrutide dose used in the trials? The Phase 2 study used 1, 4, 8, and 12 mg weekly after escalation. The Phase 3 trials used 4, 9, and 12 mg. Those are trial protocols carried out under monitoring, not a dosing guide, and there is no approved dosing because there is no approved product.
How do I get retatrutide? The only lawful route is enrollment in a clinical trial. Trials are listed on ClinicalTrials.gov.
Does dysesthesia go away when you stop? The trial reporting to date has not described lasting nerve injury, but there is no long term follow up published on this symptom specifically. That is an open question rather than a settled reassurance.
When will retatrutide be approved? No submission date has been made public by Lilly. Independent estimates generally place a possible approval no earlier than 2027.
Are the side effects worse than semaglutide? The gastrointestinal profile is broadly similar in kind and higher in rate at the top doses. Dysesthesia, reported at 12.5 percent on 12 mg in the largest trial and 20.9 percent in a smaller one, has no comparable figure in the semaglutide trials, and that is the meaningful difference so far.
Bring what you are taking
No judgment about how you got there. A physician who will look at the actual vial, run the right labs, and tell you plainly what your approved options are is more useful than another article telling you to be careful.
Sources
Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered weight loss of an average of 71.2 pounds in adults with obesity and knee osteoarthritis (TRIUMPH-4). December 11, 2025.
Eli Lilly and Company. Lilly’s triple agonist retatrutide demonstrated significant A1C and weight reductions in adults with type 2 diabetes (TRANSCEND-T2D-1). March 19, 2026.
Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered powerful weight loss in adults with obesity (TRIUMPH-1). May 21, 2026.
U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.